Economic impact of recombinant activated factor VII in the control of bleeds associated with abdominal prostatectomy

Journal of Medical Economics

Volumn 7, Issue 107-115, 2004, Pages 107-115

  Odeyemi, I A O ^a,c   Friederich, P W ^b   Levi, M ^b  

^a NOVO NORDISK A S   (Denmark)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c NONE   (United Kingdom)

Author keywords

Economics; Netherlands; NovoSeven ; Prostatectomy; Resource use; rFVIIa

Indexed keywords

HEMOSTATIC AGENT; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ARTICLE; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DOUBLE BLIND PROCEDURE; ECONOMIC ASPECT; ERYTHROCYTE CONCENTRATE; HUMAN; MALE; NETHERLANDS; OPERATION DURATION; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

EID: 5644275190     PISSN: 13696998     EISSN: None     Source Type: Journal    
DOI: 10.3111/200407107115     Document Type: Article

References (35)

1. Wilson K, Hebert PC. The challenge of increasingly expensive blood system. Canadian Medical Association Journal 2003; 168: 1149-1150.
2. Varney SJ, Guest JF. The annual cost of blood transfusion in the UK. Transfusion Medicine 2003; 13: 205-218.
3. Chamberland ME. Emerging infectious agents: do they pose a risk to the safety of transfused blood and blood products. Clinical Infectious Diseases 2002; 34: 797-305.
4. Nash PA, Schrpferman RG, Rowland RG et al. The impact of pre-donated autologous blood and intra-operative isovolaemic haemodilution on the outcome of transfusion in patients undergoing radical retro-pubic prostatectomy. British Journal of Urology 1996; 77: 856-860.
5. Dodd RV. The risk of transfusion-transmitted infection. New England Journal of Medicine 1992; 327: 419-420.
6. Gaylis FD, Friedel WE, Armas OA. Radical retro-pubic prostatectomy outcomes at a community hospital. Journal of Urology 1998; 159: 167-171.
7. Andriole GI, Smith DS, Rao G et al. Early complications of retro-pubic prostatectomy. Journal of Urology 1994; 152: 1858-1860.
8. Ness PM, Bourke DL, Walsh PC. A randomized trial of perioperative hemodilution of preoperatively deposited autologous blood in elective surgery. Transfusion 1991; 31: 226-230.
9. Goad JR, Eastham JA, Fitzgerald KB et al. Radical retropubic prostatectomy: limited benefit of autologous blood donation. Journal of Urology 1995; 154: 2103-2109.
10. Villers A, Rebillard X. [Prostate cancer surgery]. La Revue du Praticien 2003; 53: 2246-2252.
11. Melman A, Boczko J, Figueroa J et al. Critical surgical techniques for radical perineal prostatectomy. Journal of Urology 2004; 171: 786-790.
12. Hu JC, Elkin EP, Pasta DJ et al. Predicting quality of life after radical prostatectomy: results from CaPSURE. Journal of Urology 2004; 171: 703-707; discussion 707-708.
13. Cagiannos I, Karakiewicz P, Graefen M et al. Is year of radical prostatectomy a predictor of outcome in prostate cancer? Journal of Urology 2004; 171: 692-696.
14. Oefelein MG, Colangelo LA, Rademaker AW et al. Intraoperative blood loss and prognosis in prostate cancer patients undergoing radical retropubic prostatectomy. Journal of Urology 1995; 154: 442-447.
15. Goh M, Kleer CG, Kelczewski P et al. Autologous blood donation prior to anatomical radical retropubic prostatectomy: is it necessary? Urology 1997; 49: 569-574.
16. Chun TY, Martin S, Herbert L. Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology 1997; 50: 727-732.
17. Shapiro AD, Gilchrist GS, Hoots WK et al. Prospective, randomized trial of two doses of rFVIIa (NovoSeven) in haemophilia patients with inhibitors undergoing surgery. Thrombosis and Haemostasis 1998; 80: 773-778.
18. Roberts HR. Clinical experience with activated factor VII: focus on safety aspects. Blood Coagulation & Fibrinolysis 1998; 9 (Suppl 1): s115-s118.
19. Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated factor VII and activated prothrombin-complex concentrates in the treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX at a comprehensive centre in the UK. Journal of Medical Economics 2002; 5: 51-64.
20. Odeyemi IAO, Guest JF. Modelling the economic impact of recombinant activated factor VII and activated prothrombin-complex concentrates in the home treatment of a mild to moderate bleed in adults with inhibitors to clotting factors VIII and IX in the UK. Journal of Medical Economics 2002; 5: 119-133.
21. Friederich PW, Henny CP, Messelink EJ et al. Effect of recombinant activated factor VII on peri-operative blood loss in patients undergoing retro-pubic prostatectomy: a double-blind placebo-controlled randomized trial. Lancet 2003; 361: 201-205.
22. Z-index. Taxe, July 2003. Wet Tarieven Gezondheidszorg (WTG) - Geneesmiddelen. The Hague, The Netherlands.
23. Tarieflijst + Bijlage bij Tarieflijst Instellingen, College Tarieven Gezondheidszorg (CTG). July 2003. Utrecht, The Netherlands. (www.ctg-zorg.nl).
24. Tariefboek Medisch Specialisten. College Tarieven Gezondheidszorg. July 2003. Utrecht, The Netherlands.
25. Cremieux PY, Barrett B, Anderson K et al. Cost of outpatient blood transfusion in cancer patients. Journal of Clinical Oncology 2000; 18: 2755-2761.
26. Etchason J, Lawrence P, Keeler E et al. The cost effectiveness of preoperative autologous blood donations. New England Journal of Medicine 1995; 332: 719-724.
27. Sonnenberg FA. A health economic analysis of autologous transfusion. Transfusion Medicine and Hemotherapy 2002; 29: 175-183.
28. Goodnough LT, Bodner MS, Martin JW. Blood transfusion and blood conservation: cost and utilization issues. American Journal of Medical Quality 1994; 9: 172-183.
29. Makhlouf AA, Boyd JC, Chapman TN et al. Perioperative costs and charges of prostate brachytherapy and prostatectomy. Urology 2002; 60: 656-660.
30. Ramsden AR, Thurairaja R, Persad R et al. Current trends in the management of radical retropubic prostatectomy: is short-stay RRP feasible in the United Kingdom? Prostate Cancer and Prostatic Diseases 2004; 7: 50-53.
31. Smith JA Jr, Koch MO. Radical prostatectomy: balancing cost and patient care. The Canadian Journal of Urology 1997; 4 (Suppl 1): 34-38.
32. Klein EA, Kupelian PA. Localized prostate cancer: radiation or surgery? Urologie Clinics of North America 2003; 30: 315-330, ix.
33. Turini M, Redaelli A, Gramegna P et al. Quality of life and economic considerations in the management of prostate cancer. Pharmacoeconomics 2003; 21: 527-541.
34. Currie CJ, Patel, TC, McEwan P et al. Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service. Transfusion Medicine 2004, 14: 19-24.
35. Abshire T, Kenet G. Recombinant factor VIIa: review of efficacy, dosing regimens and safety in patients with congenital and acquired factor VII or IX inhibitors. Journal of Thrombosis and Haemostasis 2004, 2: 899-909.